Glucagon And Epinephrine Continue To Drive Growth At Amphastar
Primatine Mist Sales Down Slightly Due To Lower Unit Volumes
Amphastar has delivered another successful quarter, bolstered by sales of glucagon and epinephrine, as it prepares to roll out a number of commercially attractive products and complete a significant branded product acquisition.
You may also be interested in...
Although Lilly said the glucagon spray’s relatively low sales were not a factor, the pharma may be prioritizing investment on its newer diabetes and weight-loss drug Mounjaro.
Further US hybrid and generic rivals to Narcan are in the works, with Amphastar having just received an FDA nod for its naloxone nasal spray in a proprietary device as Amneal files an ANDA for a further generic version.
After shortages at competitor companies opened up gaps in the market Amphastar was able to step in to fill the void, leading to its most successful quarter yet with net revenues of $135m.